NeuroNOS announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead investigational therapy, BA-101, for the treatment of Glioblastoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
- Beyond Air subsidiary granted orphan designation for malignant glioma treatment
- Beyond Air signs international LungFit PH distribution agreements
- Beyond Air’s Earnings Call Highlights Growth and Challenges
- Beyond Air: Strong Revenue Growth and Strategic Partnerships Drive Buy Rating
- Beyond Air price target lowered to $5 from $20 at Piper Sandler